Format
Sort by
Items per page

Send to

Choose Destination

Best matches for low dose naltrexone:

Low Dose Naltrexone in the Treatment of Fibromyalgia. Metyas S et al. Curr Rheumatol Rev. (2018)

Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone. Albers LN et al. JAMA Dermatol. (2017)

Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris. Strazzulla LC et al. J Drugs Dermatol. (2017)

Search results

Items: 1 to 20 of 586

1.

The use of naltrexone in dermatology. Current evidence and future directions.

Sikora M, Rakowska A, Olszewska M, Rudnicka L.

Curr Drug Targets. 2019 Mar 18. doi: 10.2174/1389450120666190318121122. [Epub ahead of print]

PMID:
30887922
2.

The Use of Low-Dose Naltrexone for Chronic Pain.

Bostick KM, McCarter AG, Nykamp D.

Sr Care Pharm. 2019 Jan 1;34(1):43-46. doi: 10.4140/TCP.n.2019.43.

PMID:
30821677
3.
4.

Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.

Obeng S, Jali A, Zheng Y, Wang H, Schwienteck KL, Chen C, Stevens DL, Akbarali HI, Dewey WL, Banks ML, Liu-Chen LY, Selley DE, Zhang Y.

ACS Chem Neurosci. 2019 Feb 21. doi: 10.1021/acschemneuro.9b00038. [Epub ahead of print]

PMID:
30758946
5.

Variable response to low-dose naltrexone in patients with Darier disease: a case series.

Boehmer D, Eyerich K, Darsow U, Biedermann T, Zink A.

J Eur Acad Dermatol Venereol. 2019 Feb 3. doi: 10.1111/jdv.15457. [Epub ahead of print]

PMID:
30712317
6.
7.

Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats.

Smith SL, Dean RL, Todtenkopf MS, Heal DJ.

J Psychopharmacol. 2019 Mar;33(3):383-391. doi: 10.1177/0269881118822111. Epub 2019 Jan 24.

PMID:
30676189
8.

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).

Prukop T, Stenzel J, Wernick S, Kungl T, Mroczek M, Adam J, Ewers D, Nabirotchkin S, Nave KA, Hajj R, Cohen D, Sereda MW.

PLoS One. 2019 Jan 16;14(1):e0209752. doi: 10.1371/journal.pone.0209752. eCollection 2019.

9.

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.

Bolton M, Hodkinson A, Boda S, Mould A, Panagioti M, Rhodes S, Riste L, van Marwijk H.

BMC Med. 2019 Jan 15;17(1):10. doi: 10.1186/s12916-018-1242-0.

10.

The Uses of Naltrexone in Dermatological Conditions.

Lee B, Elston D.

J Am Acad Dermatol. 2018 Dec 21. pii: S0190-9622(18)33104-9. doi: 10.1016/j.jaad.2018.12.031. [Epub ahead of print] Review.

PMID:
30582992
11.

Intermittent blockade of OGFr and treatment of autoimmune disorders.

Zagon IS, McLaughlin PJ.

Exp Biol Med (Maywood). 2018 Dec;243(17-18):1323-1330. doi: 10.1177/1535370218817746. Epub 2018 Dec 12.

PMID:
30541348
12.

Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.

Ekelem C, Juhasz M, Khera P, Mesinkovska NA.

JAMA Dermatol. 2018 Nov 28. doi: 10.1001/jamadermatol.2018.4093. [Epub ahead of print]

PMID:
30484835
13.

The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma.

Machado MC, da Costa-Neto JM, Portela RD, D'Assis MJMH, Martins-Filho OA, Barrouin-Melo SM, Borges NF, Silva FL, Estrela-Lima A.

PLoS One. 2018 Oct 4;13(10):e0204830. doi: 10.1371/journal.pone.0204830. eCollection 2018.

14.

Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.

Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A.

Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1239-1248. doi: 10.1002/pds.4635. Epub 2018 Sep 25.

15.

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.

Toljan K, Vrooman B.

Med Sci (Basel). 2018 Sep 21;6(4). pii: E82. doi: 10.3390/medsci6040082. Review.

16.

Successful treatment of dermatomyositis with low-dose naltrexone.

Tran T, Chen A, Worswick S.

Dermatol Ther. 2018 Nov;31(6):e12720. doi: 10.1111/dth.12720. Epub 2018 Sep 24. No abstract available.

PMID:
30246915
17.

Treatment of psoriasis vulgaris using low-dose naltrexone.

Bridgman AC, Kirchhof MG.

JAAD Case Rep. 2018 Sep 18;4(8):827-829. doi: 10.1016/j.jdcr.2018.06.001. eCollection 2018 Sep. No abstract available.

18.

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion.

Miskoff JA, Chaudhri M.

Cureus. 2018 Jul 5;10(7):e2924. doi: 10.7759/cureus.2924.

19.

Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone.

Kollman N, Bass J.

JAAD Case Rep. 2018 Aug 16;4(7):725-727. doi: 10.1016/j.jdcr.2018.07.002. eCollection 2018 Aug. No abstract available.

20.

Naltrexone and nalmefene attenuate cocaine place preference in male mice.

Windisch KA, Reed B, Kreek MJ.

Neuropharmacology. 2018 Sep 15;140:174-183. doi: 10.1016/j.neuropharm.2018.07.025. Epub 2018 Jul 23.

PMID:
30048644

Supplemental Content

Loading ...
Support Center